Deutsche Bank AG Raises Stake in GRAIL, Inc. $GRAL

Deutsche Bank AG lifted its stake in GRAIL, Inc. (NASDAQ:GRAL) by 37.8% during the second quarter, HoldingsChannel reports. The firm owned 41,639 shares of the company’s stock after purchasing an additional 11,415 shares during the period. Deutsche Bank AG’s holdings in GRAIL were worth $2,843,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Fifth Third Bancorp boosted its position in GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after buying an additional 472 shares during the period. Comerica Bank increased its position in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of GRAIL during the fourth quarter worth approximately $28,000. Geneos Wealth Management Inc. raised its stake in shares of GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after acquiring an additional 360 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of GRAIL during the fourth quarter valued at approximately $31,000.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. TD Cowen reissued a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Robert W. Baird set a $70.00 target price on GRAIL in a research report on Wednesday, May 6th. Piper Sandler upped their target price on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Finally, The Goldman Sachs Group assumed coverage on GRAIL in a research note on Friday, June 5th. They set a “neutral” rating and a $60.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, GRAIL currently has a consensus rating of “Hold” and an average target price of $67.78.

GRAIL Stock Down 3.6%

Shares of GRAL stock opened at $79.59 on Thursday. The firm has a market cap of $3.56 billion, a price-to-earnings ratio of -8.16 and a beta of 3.24. GRAIL, Inc. has a 52-week low of $30.82 and a 52-week high of $118.84. The company’s 50 day moving average is $70.23 and its 200 day moving average is $63.65.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The company had revenue of $44.69 million during the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. Analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Insider Activity at GRAIL

In related news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. This represents a 0.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.83% of the company’s stock.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.